GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Price-to-Owner-Earnings

Actavia Life Sciences (Actavia Life Sciences) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Price-to-Owner-Earnings?

As of today (2024-05-17), Actavia Life Sciences's share price is $0.0169. Actavia Life Sciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Actavia Life Sciences's Price-to-Owner-Earnings or its related term are showing as below:


RASP's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.34
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-17), Actavia Life Sciences's share price is $0.0169. Actavia Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01. Therefore, Actavia Life Sciences's PE Ratio for today is At Loss.

As of today (2024-05-17), Actavia Life Sciences's share price is $0.0169. Actavia Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.01. Therefore, Actavia Life Sciences's PE Ratio without NRI for today is At Loss.


Actavia Life Sciences Price-to-Owner-Earnings Historical Data

The historical data trend for Actavia Life Sciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Price-to-Owner-Earnings Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actavia Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actavia Life Sciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Actavia Life Sciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Price-to-Owner-Earnings falls into.



Actavia Life Sciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Actavia Life Sciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0169/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actavia Life Sciences  (OTCPK:RASP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Actavia Life Sciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines